Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 7/20 | 1.00 |
| ▸ | MGLL | Q99685 | 4/20 | 0.63 |
| ▸ | FAAH | O00519 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2183633 | 0.85 | MGLL (0.85) | DAGLAMGLLFAAHALDH1A1TRPV1 | |
| SCHEMBL2184828 | 0.77 | MGLL (1.00) | DAGLAMGLLFAAHALDH1A1TRPV1 | |
| SCHEMBL2182851 | 0.77 | DAGLA (0.65) | DAGLAMGLLFAAHALDH1A1TRPV1 | |
| SCHEMBL2184337 | 0.74 | MGLL (0.64) | DAGLAMGLLFAAHALDH1A1TRPV1 | |
| SCHEMBL2181312 | 0.73 | MGLL (0.70) | DAGLAMGLLFAAHALDH1A1TRPV1 | |
| SCHEMBL12414610 | 0.72 | TRPV1 (0.92) | DAGLAMGLLFAAHALDH1A1TRPV1 | |
| SCHEMBL12414589 | 0.71 | TRPV1 (0.72) | DAGLAMGLLFAAHALDH1A1TRPV1 | |
| SCHEMBL12414577 | 0.71 | TRPV1 (0.72) | DAGLAMGLLFAAHALDH1A1TRPV1 | |
| SCHEMBL12414572 | 0.71 | TRPV1 (0.72) | DAGLAMGLLFAAHALDH1A1TRPV1 | |
| SCHEMBL2181664 | 0.71 | TRPV1 (0.72) | DAGLAMGLLFAAHALDH1A1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130224151-A1 | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | UNITED STATES OF AMERICA (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130150346-A1 | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome | QUEST VENTURES LTD. (GB) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130224151-A1 | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | FAAH, FAAH2, PNLIP | DAGLA 40/4885MGLL 5/4885FAAH 1/4885 |
| US-20130150346-A1 | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome | FAAH, FAAH2, MGLL | DAGLA 31/4885MGLL 3/4885FAAH 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.